アルツハイマー治療薬の世界市場レポート 2024年

アルツハイマー治療薬市場規模は近年力強く成長しています。2023年の86億4,000万米ドルから2024年には94億4,000万米ドルへと、CAGR9.3％で拡大します。過去の期間に見られた成長は、アルツハイマー病患者の増加、研究開発への投資、疾病メカニズムの理解における進歩、神経障害に取り組む世界の保健活動、一般市民の意識向上と教育活動など、いくつかの要因に起因しています。これらの要因が総合的に、アルツハイマー治療薬と関連する治療法の開発と改善に寄与しています。

2023年のアルツハイマー治療薬市場で最大の地域は北米でした。アジア太平洋は、予測期間中にアルツハイマー治療薬市場で最も急成長する地域となる見込みです。当レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 アルツハイマー治療薬市場の特徴

第3章 アルツハイマー治療薬市場の動向と戦略

第4章 アルツハイマー治療薬市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界のアルツハイマー治療薬の市場規模と成長

• 世界のアルツハイマー治療薬市場の促進要因と制約要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界のアルツハイマー治療薬の市場規模の実績と成長、2018-2023
• 世界のアルツハイマー治療薬市場の規模と成長予測、2023-2028、2033年

第6章 アルツハイマー治療薬市場セグメンテーション

• 世界のアルツハイマー治療薬市場、薬剤別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
  • ドネペジル
  • リバスチグミン
  • ガランタミン
  • メマンチン
• 世界のアルツハイマー治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
• 世界のアルツハイマー治療薬市場、用途別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
  • 初期から中期の段階
  • 中等度から重度の段階

第7章 アルツハイマー治療薬市場の地域および国分析

• 世界のアルツハイマー治療薬市場、地域別、実績および予測、2018-2023、2023-2028、2033年
• 世界のアルツハイマー治療薬市場、国別、実績および予測、2018-2023、2023-2028、2033年

第8章 アジア太平洋のアルツハイマー治療薬市場

第9章 中国のアルツハイマー治療薬市場

第10章 インドのアルツハイマー治療薬市場

第11章 日本のアルツハイマー治療薬市場

第12章 オーストラリアのアルツハイマー治療薬市場

第13章 インドネシアのアルツハイマー治療薬市場

第14章 韓国のアルツハイマー治療薬市場

第15章 西欧のアルツハイマー治療薬市場

第16章 英国のアルツハイマー治療薬市場

第17章 ドイツのアルツハイマー治療薬市場

第18章 フランスのアルツハイマー治療薬市場

第19章 イタリアのアルツハイマー治療薬市場

第20章 スペインのアルツハイマー治療薬市場

第21章 東欧のアルツハイマー治療薬市場

第22章 ロシアのアルツハイマー治療薬市場

第23章 北米アルツハイマー治療薬市場

第24章 米国のアルツハイマー治療薬市場

第25章 カナダのアルツハイマー治療薬市場

第26章 南米のアルツハイマー治療薬市場

第27章 ブラジルのアルツハイマー治療薬市場

第28章 中東のアルツハイマー治療薬市場

第29章 アフリカのアルツハイマー治療薬市場

第30章 アルツハイマー治療薬市場の競合情勢と企業プロファイル

• アルツハイマー治療薬市場の競合情勢
• アルツハイマー治療薬市場の企業プロファイル
  • AbbVie Inc.
  • Daiichi Sankyo Company Limited
  • F Hoffmann-La Roche AG
  • Merck &Co Inc.
  • Novartis AG

第31章 世界のアルツハイマー治療薬市場の競合ベンチマーキング

第32章 世界のアルツハイマー治療薬市場の競争ダッシュボード

第33章 アルツハイマー治療薬市場における主要な合併と買収

第34章 アルツハイマー治療薬市場の将来展望と可能性分析

第35章 付録

“Alzheimer's Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on Alzheimer's drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for Alzheimer's drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The Alzheimer's drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drugs: Donepezil; Rivastigmine; Galantamine; Memantine
• 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 3) By Application: Early To Moderate Stages; Moderate To Severe Stages
• Companies Mentioned: AbbVie Inc.; Daiichi Sankyo Company Limited; F Hoffmann-La Roche AG; Merck & Co Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Alzheimer's drugs are medications designed to assist in the management of symptoms related to memory loss, cognitive issues, and daily functioning challenges associated with Alzheimer's disease-a progressive brain disorder characterized by a gradual decline in memory, reasoning, and learning abilities.

The primary drugs used for Alzheimer's treatment include donepezil, rivastigmine, galantamine, and memantine. Donepezil belongs to the class of drugs known as cholinesterase inhibitors. These medications are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They find application in treating different stages of Alzheimer's disease, ranging from the early to moderate stages to the moderate to severe stages.

The Alzheimer's drugs market research report is one of a series of new reports from The Business Research Company that provides Alzheimer's drugs market statistics, including Alzheimer's drugs industry global market size, regional shares, competitors with a Alzheimer's drugs market share, detailed Alzheimer's drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Alzheimer's drugs industry. This Alzheimer's drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alzheimer's drugs market size has grown strongly in recent years. It will grow from $8.64 billion in 2023 to $9.44 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth observed during the historical period can be attributed to several factors, including the increase in Alzheimer's disease cases, investments made in research and development, advancements in the understanding of disease mechanisms, global health initiatives addressing neurological disorders, and heightened public awareness and education efforts. These factors have collectively contributed to the development and improvement of Alzheimer's drugs and associated treatments.

The alzheimer's drugs market size is expected to see strong growth in the next few years. It will grow to $13.32 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The anticipated growth in the forecast period can be attributed to various factors, including the adoption of precision medicine approaches for Alzheimer's treatment, a heightened focus on disease modification rather than just symptom management, the identification and validation of biomarkers for better diagnostics, a shift towards patient-centric drug development strategies, and an increased emphasis on non-pharmacological interventions. Key trends expected in the forecast period encompass the exploration of diverse therapeutic approaches, the integration of digital health solutions, advancements in regenerative medicine, the incorporation of sophisticated diagnostic technologies, the utilization of artificial intelligence (AI) in drug discovery processes, and a rise in partnerships and collaborations within the healthcare and pharmaceutical sectors.

The escalating prevalence of Alzheimer's disease stands as a driving force behind the anticipated growth of the Alzheimer's drugs market. This neurologic condition, characterized by progressive deterioration and brain cell degeneration, necessitates drug intervention to address memory loss, cognitive impairments, and challenges in daily functioning. These medications aim to enhance life quality and preserve independence for affected individuals. As reported in The Alzheimer's Association's 2022 Alzheimer's Disease Facts and Figures report, the staggering statistics reveal that in 2022, approximately 6.5 million Americans aged 65 and older were diagnosed with Alzheimer's disease. The prevalence of this condition rises with age, affecting 1 in 9 Americans aged 65 or older (equating to 10.7% of the total population). This percentage increases from 5.0% in individuals aged 65-74 to 33.2% in those beyond 85. Projections anticipate a surge to 88 million Americans aged 65 and older by 2050, driving the growth trajectory of the Alzheimer's drugs market due to the escalating prevalence of this disease.

The augmentation in healthcare funding is poised to steer the expansion of the Alzheimer's drugs market. Amplified financial support in healthcare channels aids extensive research and development endeavors, sustains clinical trials, fosters advanced diagnostic technologies, facilitates specialized healthcare services, drives awareness programs, and fortifies infrastructure. Notably, in September 2021, the National Institutes of Health (NIH) awarded a substantial grant of USD 1.9 million to Tabula Rasa HealthCare Inc. and Hesperos Inc., emphasizing their collaboration to explore drug-induced dementia and innovate models for advancing Alzheimer's research. This increased healthcare funding is instrumental in propelling advancements in drug development, patient care strategies, and tackling the challenges associated with Alzheimer's disease, thereby fueling the growth trajectory of the Alzheimer's drugs market.

Technological advancements signify a pivotal trend gaining traction in the Alzheimer's disease market. Major industry players are dedicatedly innovating new technologies to bolster their market standing. For example, iMediSync, a South Korea-based healthcare platform company, introduced iSyncBrain in January 2021-an EEG digital biomarker for early Alzheimer's dementia diagnosis on their AI cloud platform. This cutting-edge technology includes customized NIR-LED neuromodulation via the iSyncWave headset, enhancing neural activity through AI analytics and brain mapping techniques. Their iSyncBrain MCI classifier differentiates between amnestic mild cognitive impairment (MCI) of Alzheimer or non-Alzheimer types with over 90% accuracy, offering potential in dementia prevention during the preclinical stage, signifying a breakthrough in Alzheimer's diagnostics and intervention.

Major companies operating in the alzheimer's drugs market are developing new combination therapies to sustain their position in the market. Combination therapies refer to the simultaneous use of two or more therapeutic agents or treatment modalities to address a medical condition. For instance, in April 2022, NovaMedica LLC, a Russia-based pharmaceutical company launched an innovative Alzheimer's disease therapy named MYOREOL. The drug, developed and registered by NovaMedica, is a combination of donepezil and memantine molecules, marking the first of its kind in Russia, the EAEU, and Europe. MYOREOL aims to enhance treatment retention and effectiveness in patients with moderate and severe dementia associated with Alzheimer's disease.

In March 2022, AbbVie, a US-based publicly traded biopharmaceutical company, acquired Syndesi Therapeutics for an undisclosed amount. This acquisition grants AbbVie access to Syndesi's portfolio of new modulators of the synaptic vesicle protein 2A (SV2A), including its lead compound SDI-118, and will aid in the expansion of AbbVie's neuroscience product line. Syndesis Therapeutics is a Belgium-based company that treats Alzheimer's disease and other disorders with cognitive impairment.

Major companies operating in the alzheimer's drugs market report are: AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd .

North America was the largest region in the Alzheimer's drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer's drugs market during the forecast period. The regions covered in the alzheimer's drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the alzheimer's drugs market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Alzheimer's drugs market consists of sales of cholinesterase inhibitors such as aricept, exelon, and razadyne. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Alzheimer's Drugs Market Characteristics

3. Alzheimer's Drugs Market Trends And Strategies

4. Alzheimer's Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Alzheimer's Drugs Market Size and Growth

• 5.1. Global Alzheimer's Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Alzheimer's Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Alzheimer's Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Alzheimer's Drugs Market Segmentation

• 6.1. Global Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Donepezil
• Rivastigmine
• Galantamine
• Memantine
• 6.2. Global Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.3. Global Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Early To Moderate Stages
• Moderate To Severe Stages

7. Alzheimer's Drugs Market Regional And Country Analysis

• 7.1. Global Alzheimer's Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Alzheimer's Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Alzheimer's Drugs Market

• 8.1. Asia-Pacific Alzheimer's Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Alzheimer's Drugs Market

• 9.1. China Alzheimer's Drugs Market Overview
• 9.2. China Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Alzheimer's Drugs Market

• 10.1. India Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Alzheimer's Drugs Market

• 11.1. Japan Alzheimer's Drugs Market Overview
• 11.2. Japan Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Alzheimer's Drugs Market

• 12.1. Australia Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Alzheimer's Drugs Market

• 13.1. Indonesia Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Alzheimer's Drugs Market

• 14.1. South Korea Alzheimer's Drugs Market Overview
• 14.2. South Korea Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Alzheimer's Drugs Market

• 15.1. Western Europe Alzheimer's Drugs Market Overview
• 15.2. Western Europe Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Alzheimer's Drugs Market

• 16.1. UK Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Alzheimer's Drugs Market

• 17.1. Germany Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Alzheimer's Drugs Market

• 18.1. France Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Alzheimer's Drugs Market

• 19.1. Italy Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Alzheimer's Drugs Market

• 20.1. Spain Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Alzheimer's Drugs Market

• 21.1. Eastern Europe Alzheimer's Drugs Market Overview
• 21.2. Eastern Europe Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Alzheimer's Drugs Market

• 22.1. Russia Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Alzheimer's Drugs Market

• 23.1. North America Alzheimer's Drugs Market Overview
• 23.2. North America Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Alzheimer's Drugs Market

• 24.1. USA Alzheimer's Drugs Market Overview
• 24.2. USA Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Alzheimer's Drugs Market

• 25.1. Canada Alzheimer's Drugs Market Overview
• 25.2. Canada Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Alzheimer's Drugs Market

• 26.1. South America Alzheimer's Drugs Market Overview
• 26.2. South America Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Alzheimer's Drugs Market

• 27.1. Brazil Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Alzheimer's Drugs Market

• 28.1. Middle East Alzheimer's Drugs Market Overview
• 28.2. Middle East Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Alzheimer's Drugs Market

• 29.1. Africa Alzheimer's Drugs Market Overview
• 29.2. Africa Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Alzheimer's Drugs Market Competitive Landscape And Company Profiles

• 30.1. Alzheimer's Drugs Market Competitive Landscape
• 30.2. Alzheimer's Drugs Market Company Profiles
  • 30.2.1. AbbVie Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Daiichi Sankyo Company Limited
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F Hoffmann-La Roche AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Alzheimer's Drugs Market Competitive Benchmarking

32. Global Alzheimer's Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Alzheimer's Drugs Market

34. Alzheimer's Drugs Market Future Outlook and Potential Analysis

• 34.1 Alzheimer's Drugs Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Alzheimer's Drugs Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Alzheimer's Drugs Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer